If one is admitted to a hospital due to the severity of COVID-19 symptoms, at least be aware of what the standard operating procedure is regarding the treatment protocol. Institutional options regarding treatment are restrictive and in the case of ivermectin, prohibitive. This can result in a grim prognosis and possibly fatal outcome if a proactive stance is not taken to counter the way in which acute care facilities conduct business.
What you know or don't know upon admission may result in whether or not you leave the hospital.
Hospitals Don't Use Ivermectin. Why Not?
The mainstream media, government, and public health officials stick to the rehearsed narrative and continue to bash ivermectin as a "horse dewormer," despite decades of safe use in humans for the treatment of parasitic diseases.
The National Library of Medicine is part of the NIH. According to the NIH's website, the NLM is the world’s largest biomedical library and a leader in research in computational health informatics. NLM plays a pivotal role in translating biomedical research into practice. NLM’s research and information services support scientific discovery, health care, and public health. NLM pioneers new ways to make biomedical data and information more accessible; builds tools for better data management and personal health; and helps create a more diverse and data-skilled workforce. NLM enables researchers, clinicians, and the public to use the vast wealth of biomedical data to improve health.
Apparently, the NIH ignores its own research studies such as the one cited below which is contained in the NLM identifying ivermectin as a Covid-19 treatment option. Yet, hospitals continue to follow the tune of the NIH pied piper despite the NIH's own published research.
Viruses such as human cytomegalovirus (HCMV), human papillomavirus (HPV), Epstein–Barr virus (EBV), human immunodeficiency virus (HIV), and coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) represent a great burden to human health worldwide. FDA‐approved anti‐parasite drug ivermectin is also an antibacterial, antiviral, and anticancer agent, which offers more potentiality to improve global public health, and it can effectively inhibit the replication of SARS‐CoV‐2 in vitro.
This study, to best of our knowledge, was the first to provide ivermectin‐regulated virus‐related pathways by SILAC quantitative proteomics analysis, which revealed a broad‐spectrum antiviral property of ivermectin. More exciting thing was that the identified ivermectin‐regulated proteins included some reported SARS‐CoV‐2‐related proteins, and it could assist in exploiting potential ivermectin‐related biomarkers and the novel mechanisms in the treatment of SARS‐CoV‐2 infection. The combination of ivermectin with other drugs might result in more favorable prognoses for patients with COVID‐19. For example, one study hypothesized that the combination of hydroxychloroquine and ivermectin might show a consequential and synergistic action for treatment of COVID‐19 (Patrì & Fabbrocini, 2020). We anticipate our results to guide efforts to understand the molecular mechanisms underlying ivermectin used for the treatment of SARS‐CoV‐2 infection. Furthermore, our findings provide insight into the development of ivermectin as an option for the treatment of COVID‐19 in the context of PPPM research and practice.